Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Rochester, Minnesota 55905


RATIONALE: Aromatase inhibitor therapy is used in treating postmenopausal women who have hormone-dependent breast cancer. It is not yet known what effect aromatase inhibitor therapy has on blood vessel function. PURPOSE: This clinical trial is studying the effect of aromatase inhibitor therapy on blood vessel function in postmenopausal women with breast cancer.

Study summary:

OBJECTIVES: - Determine the effect of adjuvant aromatase inhibitor therapy on endothelial function in postmenopausal women with breast cancer. OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 treatment groups according to breast cancer hormone-receptor status (positive vs negative). - Group 1 (hormone receptor-positive): Patients receive aromatase inhibition therapy for up to 6 months in the absence of unacceptable toxicity. - Group 2 (hormone receptor-negative): Patients do not receive adjuvant treatment. Endothelial function is measured in both groups at baseline and at follow up by the room temperature peripheral arterial tonometry (RT-PAT) index using the EndoPAT method.


DISEASE CHARACTERISTICS: - Diagnosis of breast cancer - Ductal carcinoma in situ (DCIS) allowed provided the patient will not receive tamoxifen as part of treatment for their cancer - May not have had a prior mastectomy with requirement for mastectomy of the contralateral breast - No requirement for axillary lymph node dissection with a history of contralateral mastectomy and/or contralateral axillary lymph node dissection - Hormone receptor status meeting 1 of the following criteria: - Hormone receptor negative and not eligible for aromatase inhibitor therapy (AI) - Hormone receptor positive and are not receiving an AI PATIENT CHARACTERISTICS: - Postmenopausal - No known or symptomatic coronary artery disease - No significant co-morbidities, including any of the following conditions: - Active renal or hepatic disease - Known uncontrolled and/or untreated peripheral arterial disease - Uncontrolled and/or untreated hypertension - Uncontrolled and/or untreated diabetes - Uncontrolled and/or untreated hyperlipidemia PRIOR CONCURRENT THERAPY: - See Disease Characteristics - More than 7 days since prior hormone replacement therapy or hormone-based contraception - More than 12 months since prior and no concurrent tamoxifen or aromatase inhibitor therapy for this disease - More than 12 months since prior and no concurrent chemotherapy for this disease - No prior bilateral mastectomy



Primary Contact:

Principal Investigator
Nicole P. Sandhu, M.D., Ph.D.
Mayo Clinic

Backup Contact:


Location Contact:

Rochester, Minnesota 55905
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.